The disconnect between animal models of sepsis and human sepsis

Journal of Leukocyte Biology

Volumn 81, Issue 1, 2007, Pages 137-143

  Rittirsch, Daniel ^a   Hoesel, L Marco ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cecal ligation and puncture; Lipopolysaccharide; Rodents

Indexed keywords

LIPOPOLYSACCHARIDE;

ASCENDING COLON; BACTERIUM; CECUM; CLINICAL EFFECTIVENESS; HUMAN; INOCULATION; INTERMETHOD COMPARISON; LIGATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONITIS; PRIMATE; PRIORITY JOURNAL; PUNCTURE; REVIEW; RODENT; SEPSIS; STENT;

ANIMALS; CECAL DISEASES; DISEASE MODELS, ANIMAL; FECES; HUMANS; LIPOPOLYSACCHARIDES; MICE; MIDDLE AGED; PERITONITIS; SEPSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); RODENTIA;

EID: 33845905763     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0806542     Document Type: Review

References (79)

1. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M. R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310.
2. Martin, G. S., Mannino, D. M., Eaton, S., Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554.
3. Riedemann, N. C., Ward, P. A. (2003) Anti-inflammatory strategies for the treatment of sepsis. Expert Opin. Biol. Ther. 3, 339-350.
4. Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M., Sibbald, W. J. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655.
5. Riedemann, N. C., Guo, R. F., Ward, P. A. (2003) Novel strategies for the treatment of sepsis. Nat. Med. 9, 517-524.
6. Hoesel, L. M., Ward, P. A. (2004) Mechanisms of inflammatory response syndrome in sepsis. Drug Discovery Today Disease Mechanisms 1, 345-350.
7. Astiz, M. E., Rackow, E. C. (1998) Septic shock. Lancet 351, 1501-1505.
8. Oberholzer, A., Oberholzer, C., Moldawer, L. L. (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16, 83-96.
9. Angus, D. C., Wax, R. S. (2001) Epidemiology of sepsis: an update. Crit. Care Med. 29, S109-S116.
10. Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L., Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256.
11. Bone, R. C. (1991) The pathogenesis of sepsis. Ann. Intern. Med. 115, 457-469.
12. Cavaillon, J. M., Adib-Conquy, M., Fitting, C., Adrie, C., Payen, D. (2003) Cytokine cascade in sepsis. Scand. J. Infect. Dis. 35, 535-544.
13. Bergmann, M., Sautner, T. (2002) Immunomodulatory effects of vasoactive catecholamines. Wien. Klin. Wochenschr. 114, 752-761.
14. Sacerdote, P. (2006) Opioids and the immune system. Palliat. Med. 20 (Suppl. 1), S9-S15.
15. Shorr, A. F., Jackson, W. L. (2005) Transfusion practice and nosocomial infection: assessing the evidence. Curr. Opin. Crit. Care 11, 468-472.
16. Salinas, J. C., Cabezali, R., Torcal, J., Larrad, L., Sousa, R., Navarro, M., Lozano, R. (1998) Immune response and cytokines in septic rats undergoing blood transfusion. J. Surg. Res. 80, 295-299.
17. Remick, D. G., Newcomb, D. E., Bolgos, G. L., Call, D. R. (2000) Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13, 110-116.
18. Remick, D. G., Strieter, R. M., Eskandari, M. K., Nguyen, D. T., Genord, M. A., Raiford, C. L., Kunkel, S. L. (1990) Role of tumor necrosis factor-α in lipopolysaccharide-induced pathologic alterations. Am. J. Pathol. 136, 49-60.
19. Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., Wilmore, D. W. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318, 1481-1486.
20. Waage, A., Halstensen, A., Espevik, T. (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1, 355-357.
21. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
22. Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey III, T. J., Zentella, A., Albert, J. D., et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234, 470-474.
23. Okusawa, S., Gelfand, J. A., Ikejima, T., Connolly, R. J., Dinarello, C. A. (1988) Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81, 1162-1172.
24. Fisher Jr., C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M., Benjamin, E. (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702.
25. Arndt, P., Abraham, E. (2001) Immunological therapy of sepsis: experimental therapies. Intensive Care Med. 27 (Suppl. 1), S104-S115.
26. Fisher Jr., C. J., Dhainaut, J. F., Opal, S. M., Pribble, J. P., Balk, R. A., Slotman, G. J., Iberti, T. J., Rackow, E. C., Shapiro, M. J., Greenman, R. L., et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271, 1836-1843.
27. Opal, S. M., Fisher Jr., C. J., Dhainaut, J. F., Vincent, J. L., Brase, R., Lowry, S. F., Sadoff, J. C., Slotman, G. J., Levy, H., Balk, R. A., et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115-1124.
28. Eskandari, M. K., Bolgos, G., Miller, C., Nguyen, D. T., DeForge, L. E., Remick, D. G. (1992) Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148, 2724-2730.
29. Echtenacher, B., Falk, W., Mannel, D. N., Krammer, P. H. (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145, 3762-3766.
30. Echtenacher, B., Hultner, L., Mannel, D. N. (1995) Cellular and molecular mechanisms of TNF protection in septic peritonitis. J. Inflamm. 47, 85-89.
31. Wichterman, K. A., Baue, A. E., Chaudry, I. H. (1980) Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29, 189-201.
32. Postel, J., Schloerb, P. R., Furtado, D. (1975) Pathophysiologic alterations during bacterial infusions for the study of bacteremic shock. Surg. Gynecol. Obstet. 141, 683-692.
33. Cohen, J. (1999) Adjunctive therapy in sepsis: a critical analysis of the clinical trial program. Br. Med. Bull. 55, 212-225.
34. Redl, H., Bahrami, S. (2005) Large animal models: baboons for trauma, shock, and sepsis studies. Shock 24 (Suppl. 1), 88-93.
35. Martich, G. D., Danner, R. L., Ceska, M., Suffredini, A. F. (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J. Exp. Med. 173, 1021-1024.
36. Browne, M. K., Leslie, G. B. (1976) Animal models of peritonitis. Surg. Gynecol. Obstet. 143, 738-740.
37. Weinstein, W. M., Onderdonk, A. B., Bartlett, J. G., Gorbach, S. L. (1974) Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect. Immun. 10, 1250-1255.
38. Bartlett, J. G., Onderdonk, A. B., Louie, T., Kasper, D. L., Gorbach, S. L. (1978) A review. Lessons from an animal model of intra-abdominal sepsis. Arch. Surg. 113, 853-857.
39. Deitch, E. A. (2005) Rodent models of intra-abdominal infection. Shock 24 (Suppl. 1), 19-23.
40. Mathiak, G., Szewczyk, D., Abdullah, F., Ovadia, P., Feuerstein, G., Rabinovici, R. (2000) An improved clinically relevant sepsis model in the conscious rat. Crit. Care Med. 28, 1947-1952.
41. Perkash, I., Satpati, P., Agarwal, K. C., Chakravarti, R. N., Chhuttani, P. N. (1970) Prolonged peritoneal lavage in fecal peritonitis. Surgery 68, 842-845.
42. Sleeman, H. K., Diggs, J. W., Hayes, D. K., Hamit, H. F. (1969) Value of antibiotics, corticosteroids, and peritoneal lavage in the treatment of experimental peritonitis. Surgery 66, 1060-1066.
43. Hau, T., Simmons, R. L. (1977) Animal models of peritonitis. Surg. Gynecol. Obstet. 144, 755-756.
44. Nakatani, T., Sato, T., Trump, B. F., Siegel, J. H., Kobayashi, K. (1996) Manipulation of the size and clone of an intra-abdominal abscess in rats. Res. Exp. Med. (Berl.) 196, 117-126.
45. Volk, H. W., Schneider, J., Dammrich, J., Doll, W., Horl, M., Bruch, H. P. (1990) Animal model for chronic-abscess-forming peritonitis: histology and microbiology. Eur. Surg. Res. 22, 347-355.
46. Ghiselli, R., Giacometti, A., Cirioni, O., Mocchegiani, F., Orlando, F., D'Amato, G., Sisti, V., Scalise, G., Saba, V. (2004) Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock. Ann. Surg. 239, 251-256.
47. Zantl, N., Uebe, A., Neumann, B., Wagner, H., Siewert, J. R., Holzmann, B., Heidecke, C. D., Pfeffer, K. (1998) Essential role of γ interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect. Immun. 66, 2300-2309.
48. Neumann, B., Zantl, N., Veihelmann, A., Emmanuilidis, K., Pfeffer, K., Heidecke, C. D., Holzmann, B. (1999) Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Int. Immunol. 11, 217-227.
49. Maier, S., Emmanuilidis, K., Entleutner, M., Zantl, N., Werner, M., Pfeffer, K., Heidecke, C. D. (2000) Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock 14, 187-192.
50. Barthlen, W., Zantl, N., Pfeffer, K., Heidecke, C. D., Holzmann, B., Stadler, J. (1999) Impact of experimental peritonitis on bone marrow cell function. Surgery 126, 41-47.
51. Entleutner, M., Traeger, T., Westerholt, A., Holzmann, B., Stier, A., Pfeffer, K., Maier, S., Heidecke, C. D. (2006) Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal peritonitis. Int. J. Colorectal Dis. 21, 64-70.
52. Hubbard, W. J., Choudhry, M., Schwacha, M. G., Kerby, J. D., Rue III, L. W., Bland, K. I., Chaudry, I. H. (2005) Cecal ligation and puncture. Shock 24 (Suppl. 1), 52-57.
53. Ayala, A., Chaudry, I. H. (1996) Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6 (Suppl. 1), S27-S38.
54. Song, M., Kellum, J. A. (2005) Interleukin-6. Crit. Care Med. 33, S463-S465.
55. Turnbull, I. R., Javadi, P., Buchman, T. G., Hotchkiss, R. S., Karl, I. E., Coopersmith, C. M. (2004) Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21, 121-125.
56. Czermak, B. J., Sarma, V., Pierson, C. L., Warner, R. L., Huber-Lang, M., Bless, N. M., Schmal, H., Friedl, H. P., Ward, P. A. (1999) Protective effects of C5a blockade in sepsis. Nat. Med. 5, 788-792.
57. Huber-Lang, M., Sarma, V. J., Lu, K. T., McGuire, S. R., Padgaonkar, V. A., Guo, R. F., Younkin, E. M., Kunkel, R. G., Ding, J., Erickson, R., Curnutte, J. T., Ward, P. A. (2001) Role of C5a in multiorgan failure during sepsis. J. Immunol. 166, 1193-1199.
58. Riedemann, N. C., Neff, T. A., Guo, R. F., Bernacki, K. D., Laudes, I. J., Sarma, J. V., Lambris, J. D., Ward, P. A. (2003) Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170, 503-507.
59. Singleton, K. D., Wischmeyer, P. E. (2003) Distance of cecum ligated influences mortality, tumor necrosis factor-α and interleukin-6 expression following cecal ligation and puncture in the rat. Eur. Surg. Res. 35, 486-491.
60. Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., Cerami, A. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664.
61. Minnema, M. C., Chang, A. C., Jansen, P. M., Lubbers, Y. T., Pratt, B. M., Whittaker, B. G., Taylor, F. B., Hack, C. E., Friedman, B. (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95, 1117-1123.
62. Bengtsson, A., Redl, H., Schlag, G., Hogasen, K., Gotze, O., Mollnes, T. E. (1998) Anti-TNF treatment of baboons with sepsis reduces TNF-α, IL-6 and IL-8, but not the degree of complement activation. Scand. J. Immunol. 48, 509-514.
63. Stevens, J. H., O'Hanley, P., Shapiro, J. M., Mihm, F. G., Satoh, P. S., Collins, J. A., Raffin, T. A. (1986) Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77, 1812-1816.
64. Hangen, D. H., Stevens, J. H., Satoh, P. S., Hall, E. W., O'Hanley, P. T., Raffin, T. A. (1989) Complement levels in septic primates treated with anti-C5a antibodies. J. Surg. Res. 46, 195-199.
65. Haudek, S. B., Natmessnig, B. E., Furst, W., Bahrami, S., Schlag, G., Redl, H. (2003) Lipopolysaccharide dose response in baboons. Shock 20, 431-436.
66. Taylor Jr., F. B. (2001) Response of anticoagulant pathways in disseminated intravascular coagulation. Semin. Thromb. Hemost. 27, 619-631.
67. Deitch, E. A. (1998) Animal models of sepsis and shock: a review and lessons learned. Shock 9, 1-11.
68. Remick, D. G., Ward, P. A. (2005) Evaluation of endotoxin models for the study of sepsis. Shock 24 (Suppl.) 1, 7-11.
69. Marshall, J. C., Deitch, E., Moldawer, L. L., Opal, S., Redl, H., van der Poll, T. (2005) Preclinical models of shock and sepsis: what can they tell us? Shock 24 (Suppl. 1), 1-6.
70. Van der Poll, T. (2001) Immunotherapy of sepsis. Lancet Infect. Dis. 1, 165-174.
71. Bernard, G. R., Vincent, J. L., Laterre, P. F., LaRosa, S. P., Dhainaut, J. F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., Fisher Jr., C. J. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709.
72. Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., Bouillon, R. (2001) Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345, 1359-1367.
73. Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., Tomlanovich, M. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377.
74. De Beer, F. C., Baltz, M. L., Munn, E. A., Feinstein, A., Taylor, J., Bruton, C., Clamp, J. R., Pepys, M. B. (1982) Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 45, 55-70.
75. Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Gallimore, J. R., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440, 1217-1221.
76. Beutler, B., Rehli, M. (2002) Evolution of the TIR, Tolls and TLRs: functional inferences from computational biology. Curr. Top. Microbiol. Immunol. 270, 1-21.
77. Vincent, J. L. (1997) Dear SIRS, I'm sorry to say that I don't like you. Crit. Care Med. 25, 372-374.
78. Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., Natanson, C. (2002) Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205.
79. Huber-Lang, M., Sarma, J. V., Rittirsch, D., Schreiber, H., Weiss, M., Flierl, M., Younkin, E., Schneider, M., Suger-Wiedeck, H., Gebhard, F., et al. (2005) Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 174, 1104-1110.